Core Viewpoint - Large-cap biotech stocks are considered resilient to disruption risks typically faced by tech companies, primarily due to their long drug approval processes and established product portfolios [1][2] Group 1: Biotech Sector Resilience - Companies like Amgen and AbbVie are highlighted for their ability to navigate revenue erosion through broad product portfolios and multi-year pipeline replacements [1] - The FDA approval process, which can take a decade, provides a structural time buffer that protects biotech firms from rapid obsolescence [1] - Year-to-date performance shows Amgen up 16% and Gilead up 21% in 2026, significantly outperforming the iShares Biotechnology ETF, which is up approximately 3% [1] Group 2: Disruption Mechanisms - While biotech firms are insulated from AI-driven disruption, they face challenges such as patent cliffs, biosimilar competition, and government drug pricing reforms [1] - AbbVie’s Humira lost exclusivity, leading to a revenue drop of about 50% in two years, highlighting the risks associated with patent cliffs [1] - Amgen's revenue from Enbrel fell 48% in Q4 2025 due to biosimilar competition and Medicare redesign, indicating structural revenue erosion [1] Group 3: Company-Specific Insights - Gilead's ASCENT-07 trial for Trodelvy missed its primary endpoint, demonstrating how clinical trial failures can significantly impact pipeline value [2] - Eli Lilly's stock has appreciated approximately 416% over five years, driven by the success of its GLP-1 products, but it is down 6% year-to-date in 2026 [2] - Biogen's revenue is expected to decline mid-single digits in 2026, with its MS franchise down 14% in Q4 2025, reflecting a different risk profile compared to other biotech firms [2] Group 4: Evaluating Biotech Stocks - Investors should assess biotech stocks based on three questions: the percentage of revenue from products with patent protection beyond five years, the presence of at least two Phase 3 pipeline products, and the strength of the balance sheet to support pipeline investments [2] - Amgen's CEO expressed confidence in the company's broad portfolio and innovative therapies, indicating a path for sustained long-term growth [2] - Understanding the specific types of disruption, such as patent cliffs and pricing reform, is crucial for investors to navigate volatility in the biotech sector [2]

Core Insights - The company exited 2025 with strong momentum, achieving double-digit growth in both revenue and earnings per share, supported by 13 products delivering double-digit growth and 14 products exceeding $1 billion in annual sales [2][3] Group 1: Growth Drivers - The momentum is driven by six key growth drivers: Repatha, EVENITY, TEZSPIRE, rare disease treatments, innovative oncology, and the biosimilars portfolio [3] - Repatha, EVENITY, and TEZSPIRE each grew over 30% year-over-year in 2025, achieving record sales and representing multibillion-dollar global franchises [3] - These medicines address significant unmet medical needs, with millions of patients yet to be treated, indicating strong growth potential not only for 2026 but for the entire decade [3]

Summary of Amgen's Conference Call Company Overview - **Company**: Amgen - **Event**: 46th Annual TD Cowen Healthcare Conference - **Key Participants**: Justin Claeys (SVP of Finance), Kave Niksefat (SVP of Global Marketing and Access), Casey Capparelli (Head of IR) Core Industry Insights Financial Performance - Amgen exited 2025 with strong momentum, with 13 products delivering double-digit growth and 14 products exceeding $1 billion in annual sales [2][10] - The company reported double-digit growth in both revenue and earnings per share for 2025, supported by six key growth drivers: Repatha, EVENITY, TEZSPIRE, rare disease portfolio, innovative oncology, and biosimilars [2][10] Product Performance - **Repatha, EVENITY, TEZSPIRE**: Each grew over 30% year-over-year in 2025, representing multi-billion dollar global franchises [2] - **Rare Disease Portfolio**: Generated $5 billion in sales for 2025, up 14% year-over-year, driven by new patient reach and geographic expansion [3] - **Uplizna**: Grew 73% in 2025, with expectations for continued growth following recent approvals [3] - **Biosimilars Portfolio**: Generated $3 billion in sales, growing 37% year-over-year, with strong uptake of PAVBLU [4] Pipeline Developments - 2026 is expected to be a disciplined data year with multiple phase 2 and phase 3 programs [5] - **MariTide**: Positioned as a differentiated treatment for obesity and Type 2 diabetes, with a unique dosing schedule [5] - **Olpasiran**: A small interfering RNA medicine targeting Lp(a), with ongoing studies [6] - **Dazodalibep**: Targeting Sjögren's disease, with two phase III studies expected to complete in the second half of 2026 [6] Market Dynamics Competitive Landscape - Increased competition in the cardiometabolic market, with new entrants expected to grow overall market penetration rather than just share [20] - Amgen's Repatha has a competitive edge due to extensive clinical data, including unique primary prevention data [21] Access and Pricing Strategies - Amgen has successfully negotiated access across various therapeutic areas, ensuring affordability and accessibility of its medicines [12] - **AmgenNow**: A direct-to-patient program for Repatha priced at $239 per month, aimed at uninsured or high-deductible patients [17][18] - The average copay for Repatha has decreased to less than $50 a month, with over half of Medicare patients no longer requiring prior authorization [16] Challenges - Otezla faces European generic competition, with sales of $282 million in 2025 and expected erosion in 2026 due to biosimilar competition [9] - The first quarter of the year typically sees lower sales due to seasonal headwinds and inventory build from the previous quarter [8][9] Additional Insights - The company is focusing on expanding its market share in severe asthma with TEZSPIRE, which can be used across different patient phenotypes [22][24] - Uplizna is being utilized across all lines of therapy, with a significant portion of prescriptions coming from bio-naive patients [28] - The European market remains challenging, but there are signs of governments beginning to react positively to drug pricing and access [33] Conclusion Amgen is well-positioned for sustained long-term growth with a diversified portfolio and a robust pipeline. The company is navigating competitive pressures while focusing on access and affordability for its products, particularly in the cardiometabolic and rare disease markets.

Core Insights - Amgen Inc. is recognized as one of the 13 Best NASDAQ Dividend Stocks to buy currently [1] - Barclays initiated coverage of Amgen with an Equal Weight rating and a price target of $185, indicating ongoing uncertainty regarding the Phase 3 MARITIME trial results [2] - Amgen's Q4 2025 earnings report highlighted strong performance, with 14 products achieving over $1 billion in annual sales and double-digit growth in revenue and earnings per share [3] Group 1: Financial Performance - Amgen's portfolio includes 14 blockbuster products, with 13 products showing double-digit growth and 18 achieving record results [3] - Key products such as Repatha, EVENITY, and TEZSPIRE experienced growth exceeding 30% year-over-year, contributing significantly to long-term growth [4] - The rare disease segment generated over $5 billion in revenue, while oncology growth was bolstered by the BiTE platform, particularly IMDELLTRA, which has become a standard treatment for certain lung cancer patients [4] Group 2: Market Position and Outlook - The company operates in the biotechnology sector, focusing on developing treatments for serious diseases with high unmet medical needs [5] - Barclays expressed a more cautious outlook compared to the broader market, although Amgen's strong guidance helps mitigate concerns [2] - The ongoing debate surrounding the MARITIME trial results is expected to persist, impacting investor sentiment [2]

Summary of Amgen Conference Call - February 12, 2026 Company Overview - **Company**: Amgen (NasdaqGS:AMGN) - **Focus**: Development of innovative therapies for autoimmune diseases and other conditions Key Products and Developments UPLIZNA - **Indications**: Plans to initiate Phase III studies for autoimmune hepatitis (AIH) and chronic inflammatory demyelinating polyneuropathy (CIDP) later in 2026 - **Mechanism**: B-cell depleter targeting CD19, effective in conditions driven by pathogenic B-cells - **Market Potential**: - CIDP prevalent pool in the U.S. estimated at 35,000 patients, with 7,000-10,000 new cases annually - AIH likely has a larger patient population, though exact numbers are difficult to ascertain - **Rationale**: Proven effectiveness in similar conditions like IgG4-related disease and generalized myasthenia gravis supports the potential for UPLIZNA in AIH and CIDP [1][2][3][4][6] Daxdilimab - **Indications**: Positive Phase II results in discoid lupus; previously failed in systemic lupus erythematosus (SLE) - **Mechanism**: Targets immunoglobulin-like transcript seven protein (ILT-7), depleting plasmacytoid dendritic cells involved in interferon production - **Clinical Results**: - Discoid lupus study met primary endpoint of reduced disease severity at week 24 - Secondary endpoint also showed clinical benefit - **Future Plans**: Considering Phase III study for discoid lupus, with potential for broader indications in autoimmune diseases driven by plasmacytoid dendritic cells [9][10][11][13][16] Dazodalibep - **Indications**: Targeting Sjögren's syndrome with two ongoing Phase III studies - **Mechanism**: Inhibits CD40 ligand, disrupting B-cell activation and downstream inflammatory cascades - **Clinical Management**: Current management is symptomatic; no definitive treatments exist - **Phase II Results**: Showed improvement in disease activity index and patient-reported outcomes, providing confidence for Phase III studies [18][26][29][32] TEZSPIRE - **Indications**: Recently expanded label for chronic rhinosinusitis with nasal polyps - **Mechanism**: Targets TSLP, addressing upstream drivers of inflammation, differentiating it from therapies targeting downstream cytokines (IL-4, IL-5, IL-13) - **Clinical Results**: Phase 3 Waypoint study showed significant reduction in nasal polyp severity and decreased need for surgery - **Market Potential**: High overlap between chronic rhinosinusitis and asthma (approximately 20% of asthma patients also have nasal polyps), enhancing TEZSPIRE's market reach [35][36][37][42][45] Eosinophilic Esophagitis (EoE) - **Unmet Need**: Current treatments are limited, primarily involving proton pump inhibitors and corticosteroids - **Prevalence**: Estimated at 1 in 700 people in the U.S. - **Phase III Study**: Expected data in the second half of 2026, with potential for TEZSPIRE to address this unmet need [47][49][51] Competitive Landscape - **Dazodalibep vs. Nipocalimab**: Dazodalibep is the first therapy to demonstrate efficacy in both subgroups of Sjögren's syndrome in Phase II, with ongoing Phase III studies to confirm its effectiveness [32][34] Future Outlook - **Execution Focus**: Amgen aims to build penetration in existing indications before exploring new ones for TSLP-targeted therapies - **Inhaled TSLP Therapy**: AMG 104, an inhaled TSLP antibody fragment, is in Phase II trials, with potential to provide an alternative to injected biologics for asthma management [65][66][70][74] Conclusion - Amgen is positioned to leverage its innovative therapies across multiple autoimmune conditions, with significant clinical data supporting the efficacy of its products. The company is focused on executing its current strategies while preparing for future opportunities in the evolving therapeutic landscape.

Core Insights - Amgen reported revenue of $9.56 billion for the quarter ended September 2025, reflecting a 12.4% increase year-over-year and a 6.87% surprise over the Zacks Consensus Estimate of $8.94 billion [1] - The earnings per share (EPS) for the quarter was $5.64, which is an increase from $5.58 in the same quarter last year, resulting in a 12.8% surprise over the consensus EPS estimate of $5.00 [1] Financial Performance Metrics - Product sales for Neulasta in the ROW were $20 million, slightly above the estimated $19.55 million, but down 23.1% year-over-year [4] - Neulasta sales in the U.S. reached $72 million, exceeding the estimate of $60.9 million, but down 14.3% from the previous year [4] - XGEVA sales in the ROW were $182 million, surpassing the average estimate of $144.77 million, marking an 8.3% year-over-year increase [4] - Enbrel sales in the ROW were $6 million, below the estimated $7.36 million, reflecting a 25% decline year-over-year [4] - Other revenues amounted to $420 million, exceeding the average estimate of $373.34 million, with a year-over-year increase of 19.3% [4] - Total product sales were $9.14 billion, surpassing the estimated $8.55 billion, representing a 12.1% increase year-over-year [4] - BLINCYTO total sales were $392 million, slightly below the estimate of $412.7 million, but showing a 19.9% increase year-over-year [4] - Otezla total sales reached $585 million, slightly above the estimate of $582.08 million, with a year-over-year increase of 3.7% [4] - Total sales for Neulasta were $92 million, exceeding the estimate of $79.77 million, but down 16.4% year-over-year [4] - Enbrel total sales were $580 million, below the estimate of $645.48 million, reflecting a 29.7% decline year-over-year [4] - LUMAKRAS/LUMYKRAS total sales were $96 million, slightly below the estimate of $100.05 million, down 2% year-over-year [4] - TEZSPIRE total sales were $377 million, exceeding the estimate of $364.18 million, with a significant year-over-year increase of 40.2% [4] Stock Performance - Amgen's shares returned +0.7% over the past month, compared to the Zacks S&P 500 composite's +2.1% change, indicating a performance in line with the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]

Core Insights - Amgen reported strong financial results for Q3 2025, with total revenues increasing by 12% to $9.6 billion compared to Q3 2024, driven by a 14% volume growth in product sales, despite a 4% decrease in net selling prices [6][16][17] Financial Performance - Total revenues for Q3 2025 reached $9.6 billion, a 12% increase from Q3 2024 [6] - Product sales grew by 12%, with 14% volume growth offset by a 4% decline in net selling prices [6] - GAAP EPS rose 14% from $5.22 to $5.93, while non-GAAP EPS increased by 1% from $5.58 to $5.64 [6][11] - Free cash flow for Q3 2025 was $4.2 billion, up from $3.3 billion in Q3 2024 [13][16] Product Sales Highlights - Sixteen products achieved double-digit sales growth, including Repatha (40% increase), EVENITY (36% increase), and TEZSPIRE (40% increase) [6][8] - Enbrel sales decreased by 30% year-over-year, primarily due to a 38% drop in net selling price [6][8] - Ultra-Rare products generated $200 million in sales, a 6% increase year-over-year [8] Operating Expenses and Margins - Total operating expenses increased by 9% year-over-year, with R&D expenses rising by 31% due to higher spending on late-stage clinical programs [11][12] - GAAP operating income increased from $2.0 billion to $2.5 billion, with an operating margin of 27.6%, up 2.5 percentage points [11][12] - Non-GAAP operating margin decreased by 2.5 percentage points to 47.1% [11][12] Cash Flow and Balance Sheet - Operating cash flow for Q3 2025 was $4.7 billion, compared to $3.6 billion in Q3 2024 [13] - Cash and cash equivalents totaled $9.4 billion, while debt outstanding was $54.6 billion as of September 30, 2025 [13][16] Guidance for 2025 - The company expects total revenues for 2025 to be in the range of $35.8 billion to $36.6 billion, with GAAP EPS projected between $13.76 and $14.60 [17]

Core Insights - Amgen reported a strong Q2 2025 with a 9% increase in GAAP revenue to $9.18 billion and a non-GAAP EPS of $6.02, exceeding analyst expectations [1][2][5] - The company emphasized pipeline advancements and product launches as key drivers of growth, despite a decline in free cash flow [1][4][5] Financial Performance - Non-GAAP EPS reached $6.02, a 21% increase from $4.97 in Q2 2024, surpassing the consensus estimate of $5.28 [2][5] - GAAP revenue was $9.18 billion, up 9% year-over-year, compared to $8.4 billion in Q2 2024 [2][5] - Non-GAAP operating margin improved to 48.9%, a 0.7 percentage point increase from the previous year [2][6] - Free cash flow decreased to $1.9 billion from $2.2 billion in Q2 2024, attributed to higher capital spending and tax payment timing [2][5][15] Product Performance - Sales growth varied across product lines, with Repatha and EVENITY increasing over 30%, while Prolia saw a 4% decline [7][8] - Rare disease products UPLIZNA and TAVNEOS experienced significant revenue increases of 91% and 55%, respectively [7][11] - Inflammation products showed mixed results, with TEZSPIRE growing 46% and Enbrel declining 34% [8] - Oncology products like IMDELLTRA reported strong growth, while older drugs faced competitive pressures [12][13] Pipeline and Innovation - Amgen's pipeline includes promising candidates like MariTide for obesity, which showed strong phase 2 data [10][12] - UPLIZNA is under FDA review for generalized myasthenia gravis, with a decision expected by December 14, 2025 [11] - The company is focusing on expanding its biosimilars portfolio, although pricing pressures are increasing [13][16] Strategic Focus - Amgen is committed to expanding its product pipeline and international market presence while investing in advanced manufacturing [4][16] - The company plans to maintain a capital spending target of $2.3 billion and has set a revenue target of $35.0–$36.0 billion for FY2025 [17][18] - Management highlighted the importance of new drug approvals and the impact of biosimilar competition on established products as key areas to monitor [19]